NovaRock Biotherapeutics to Present at the 10th Annual Immuno-Oncology Summit 2022

Ewing, NJ, October 13, 2022 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody therapies for cancer and inflammatory diseases announced today that Dr. Raymond Yu, Director of Preclinical, will present at the 10th Annual Immuno-Oncology Summit 2022 held in Boston, Massachusetts and on October 12-14, 2022.  Dr. Yu’s oral presentation highlights our highly potent and safe CD137 Bispecific Antibody Platform for the Development of Solid Tumor Therapeutics.

Date:  Thursday, October 13, 2022, at 11:30EST

Abstract: First-generation CD137 agonists reached limited clinical outcomes due to hepatotoxicity and/or poor efficacy. With a “fit-for-purpose” design, NovaRock developed a CD137 bispecific platform to activate the co-stimulatory pathway through TAA-mediated receptor clustering. These bispecific antibodies reprogram the tumor microenvironment to elicit potent anti-tumor effects without detectable toxicity and long-lasting immunological memory. Additionally, these antibodies have been optimized to facilitate development and manufacturing. The lead antibody NBL-028 is currently in the IND-enabling stage.